How can Cytokine-induced killer cells overcome CAR-T cell limits

The successful treatment of patients affected by B-cell malignancies with Chimeric Antigen Receptor (CAR)-T cells represented a breakthrough in the field of adoptive cell therapy (ACT). However, CAR-T therapy is not an option for every patient, and several needs remain unmet. In particular, the prod...

Descripción completa

Detalles Bibliográficos
Autores principales: Cappuzzello, Elisa, Vigolo, Emilia, D’Accardio, Giulia, Astori, Giuseppe, Rosato, Antonio, Sommaggio, Roberta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477668/
https://www.ncbi.nlm.nih.gov/pubmed/37675107
http://dx.doi.org/10.3389/fimmu.2023.1229540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477668/
https://www.ncbi.nlm.nih.gov/pubmed/37675107
http://dx.doi.org/10.3389/fimmu.2023.1229540

Ejemplares similares